HTL vs. QIPT, CPH, OGI, MDNA, CRDL, VHI, HLS, DR, SVA, and EDT
Should you be buying Hamilton Thorne stock or one of its competitors? The main competitors of Hamilton Thorne include Quipt Home Medical (QIPT), Cipher Pharmaceuticals (CPH), Organigram (OGI), Medicenna Therapeutics (MDNA), Cardiol Therapeutics (CRDL), Vitalhub (VHI), HLS Therapeutics (HLS), Medical Facilities (DR), Sernova (SVA), and Spectral Medical (EDT). These companies are all part of the "medical" sector.
Quipt Home Medical (TSE:QIPT) and Hamilton Thorne (TSE:HTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Quipt Home Medical received 11 more outperform votes than Hamilton Thorne when rated by MarketBeat users. However, 100.00% of users gave Hamilton Thorne an outperform vote while only 80.00% of users gave Quipt Home Medical an outperform vote.
Hamilton Thorne has a net margin of -0.90% compared to Hamilton Thorne's net margin of -1.57%. Quipt Home Medical's return on equity of -1.00% beat Hamilton Thorne's return on equity.
Quipt Home Medical has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Hamilton Thorne has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.
Hamilton Thorne has lower revenue, but higher earnings than Quipt Home Medical. Hamilton Thorne is trading at a lower price-to-earnings ratio than Quipt Home Medical, indicating that it is currently the more affordable of the two stocks.
45.7% of Quipt Home Medical shares are owned by institutional investors. Comparatively, 19.5% of Hamilton Thorne shares are owned by institutional investors. 3.9% of Quipt Home Medical shares are owned by company insiders. Comparatively, 27.8% of Hamilton Thorne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Quipt Home Medical currently has a consensus price target of C$11.74, suggesting a potential upside of 117.81%. Given Hamilton Thorne's stronger consensus rating and higher possible upside, equities research analysts plainly believe Quipt Home Medical is more favorable than Hamilton Thorne.
In the previous week, Hamilton Thorne's average media sentiment score of 0.00 beat Quipt Home Medical's score of -0.31 indicating that Quipt Home Medical is being referred to more favorably in the media.
Summary
Quipt Home Medical beats Hamilton Thorne on 10 of the 18 factors compared between the two stocks.
Get Hamilton Thorne News Delivered to You Automatically
Sign up to receive the latest news and ratings for HTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hamilton Thorne Competitors List
Related Companies and Tools
